Torii Pharmaceutical Co Ltd
TSE:4551

Watchlist Manager
Torii Pharmaceutical Co Ltd Logo
Torii Pharmaceutical Co Ltd
TSE:4551
Watchlist
Price: 4 760 JPY 2.04% Market Closed
Market Cap: 133.8B JPY
Have any thoughts about
Torii Pharmaceutical Co Ltd?
Write Note

Torii Pharmaceutical Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Torii Pharmaceutical Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Torii Pharmaceutical Co Ltd
TSE:4551
Operating Income
ÂĄ6.5B
CAGR 3-Years
14%
CAGR 5-Years
20%
CAGR 10-Years
3%
Takeda Pharmaceutical Co Ltd
TSE:4502
Operating Income
ÂĄ541.9B
CAGR 3-Years
-10%
CAGR 5-Years
18%
CAGR 10-Years
16%
Daiichi Sankyo Co Ltd
TSE:4568
Operating Income
ÂĄ303.4B
CAGR 3-Years
50%
CAGR 5-Years
22%
CAGR 10-Years
10%
Otsuka Holdings Co Ltd
TSE:4578
Operating Income
ÂĄ400.1B
CAGR 3-Years
30%
CAGR 5-Years
26%
CAGR 10-Years
6%
Chugai Pharmaceutical Co Ltd
TSE:4519
Operating Income
ÂĄ540.2B
CAGR 3-Years
15%
CAGR 5-Years
24%
CAGR 10-Years
21%
Astellas Pharma Inc
TSE:4503
Operating Income
ÂĄ130.6B
CAGR 3-Years
-1%
CAGR 5-Years
-13%
CAGR 10-Years
-1%
No Stocks Found

Torii Pharmaceutical Co Ltd
Glance View

Market Cap
133.8B JPY
Industry
Pharmaceuticals

Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

Intrinsic Value
3 379.07 JPY
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Torii Pharmaceutical Co Ltd's Operating Income?
Operating Income
6.5B JPY

Based on the financial report for Sep 30, 2024, Torii Pharmaceutical Co Ltd's Operating Income amounts to 6.5B JPY.

What is Torii Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
3%

Over the last year, the Operating Income growth was 38%. The average annual Operating Income growth rates for Torii Pharmaceutical Co Ltd have been 14% over the past three years , 20% over the past five years , and 3% over the past ten years .

Back to Top